Table 4.

The Results of Sensitivity Analysis for Relapse Prevention

		Number of Studies	Number of Patients	I2	Risk Ratio	95% Confidence Interval	P	I2	Number Needed to Treat	95% Confidence Interval	P
Study duration	Long (≥ 15 months)	3	342	69%	1.20	0.65 to 2.19	.56
	Short (< 15 months)	3	218	0%	0.61	0.46 to 0.81	.0008		ns
Blinding	Double blind	2	385	92%	0.92	0.29 to 2.91	.89
	Open	4	175	0%	0.75	0.58 to 0.97	.03		ns
Comparator	Second generation antipsychotic monotherapy	3	349	69%	1.18	0.69 to 2.02	.55
	Other oral medications *	3	211	0%	0.59	0.44 to 0.80	.0005		ns
Type of bipolar disorder	Rapid cycling or high frequency of relapse patients	2	169	0%	0.58	0.43 to 0.79	.0004	0%	-4	-7 to -3	<.0001
	Others	4	391	31%	1.19	0.74 to 1.91	.48
Long-acting injectable antipsychotics	Risperidone long-acting injectable	5	518	79%	0.86	0.54 to 1.36	.51
	Flupenthixol decanoate	1	42	na	1.36	0.13 to 13.84	.80
Sample size	Large (total number of patients > 100)	2	385	92%	0.92	0.29 to 2.91	.89
	Small (total number of patients < 100)	4	175	0%	0.75	0.58 to 0.97	.03		ns

Abbreviations: na, not applicable; ns, not significant.

*Others: Mood stabilizers, antidepressants, antipsychotic or any combination of these agents